Commerce and Industry Minister Piyush Goyal on Tuesday, 9 June declared India well-positioned to emerge as the world's preferred pharmaceutical manufacturer, contract manufacturing destination, and supplier of affordable medicines, addressing the Global Ambassador Meet on the Pharmaceutical Sector in New Delhi. The minister's remarks came as India's pharma exports crossed $31 billion in FY 2025-26, nearly doubling from $14 billion in FY 2014-15.

Key Developments at the Global Ambassador Meet

Goyal underscored that Indian medicines are now reaching patients in more than 200 countries, backed by the industry's established quality standards and expanding manufacturing capabilities. He invited global companies to invest, manufacture, and collaborate in India, positioning the country as a hub not just for generics but for innovation-driven pharmaceutical growth.

The minister described iPHEX 2026 — scheduled at Bharat Mandapam, New Delhi from 7 to 9 September — as a critical showcase platform. He urged Ambassadors, High Commissioners, and representatives of foreign missions present at the meet to encourage participation from their respective countries. The event is expected to draw more than 700 exhibitors, over 600 overseas business delegates, and around 25,000 domestic visitors.

India's $50 Billion Pharma Export Target by 2030

Commerce Secretary Rajesh Agrawal laid out India's ambition to achieve $50 billion in pharmaceutical exports by 2030, driven by quality upgrades, innovation, regulatory excellence, and market diversification. He noted that India currently operates more than 10,500 manufacturing units and offers over 60,000 generic brands across 60 therapeutic categories.

Agrawal further highlighted that over 60 per cent of India's pharmaceutical exports are directed to highly regulated markets — a figure that reflects growing international confidence in Indian manufacturing standards. This comes amid a global push by several countries to reduce dependence on single-source supply chains, a dynamic that has worked in India's favour since the COVID-19 pandemic.

iPHEX 2026 and Global Drug Regulatory Conclave Launched

The occasion also saw the formal launch of the Curtain Raiser for the Global Drug Regulatory Conclave 2026, scheduled for 30–31 July. The Conclave is expected to bring together regulators, policymakers, and industry leaders globally to deliberate on regulatory convergence, mutual reliance mechanisms, and emerging challenges in pharmaceutical regulation.

A promotional video for both iPHEX 2026 and the Global Drug Regulatory Conclave 2026 was released at the event. The Global Ambassador Meet itself witnessed participation from diplomats of 98 countries, alongside pharmaceutical industry representatives, regulators, healthcare stakeholders, and senior government officials.

India's Pharma Sector: From Generics to Innovation

Notably, while India's dominance in generic medicines remains intact, the sector is increasingly pivoting toward higher-value products, advanced healthcare technologies, and research-driven growth. Goyal's remarks signal a deliberate policy push to reframe India's pharmaceutical identity — from a low-cost supplier to a trusted, innovation-capable partner for the global healthcare ecosystem.

With iPHEX 2026 and the Regulatory Conclave both on the horizon, the coming months will test whether this diplomatic and institutional momentum translates into binding investment commitments and long-term supply partnerships.